April 4 (Reuters) - The Canadian health regulator said on Thursday it was advising Allergan (NYSE:AGN) Plc AGN.N that it plans to suspend the license for the Botox-maker's Biocell breast implants.
Health Canada said its move followed the completion of its assessment of textured breast implants as part of a larger ongoing safety review.